Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BCYC Stock Alerts

Bicycle Therapeutics (BCYC) Competitors

Bicycle Therapeutics logo
$3.90 -0.08 (-2.01%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 +0.02 (+0.49%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BCYC vs. ALVO, REPL, JBIO, FBRX, and ODTX

Should you buy Bicycle Therapeutics stock or one of its competitors? Bicycle Therapeutics's main competitors and comparable companies include Alvotech (ALVO), Replimune Group (REPL), Jade Biosciences (JBIO), Forte Biosciences (FBRX), and Odyssey Therapeutics (ODTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bicycle Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alvotech has higher revenue and earnings than Bicycle Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$588.90M2.08$27.92M-$0.25N/A
Bicycle Therapeutics$72.86M3.75-$218.96M-$2.73N/A

In the previous week, Alvotech had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Alvotech and 3 mentions for Bicycle Therapeutics. Alvotech's average media sentiment score of 0.97 beat Bicycle Therapeutics' score of 0.86 indicating that Alvotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicycle Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Alvotech has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Alvotech has a net margin of -14.36% compared to Bicycle Therapeutics' net margin of -311.11%. Alvotech's return on equity of -11.92% beat Bicycle Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech-14.36% -11.92% -7.59%
Bicycle Therapeutics -311.11%-33.22%-27.79%

Alvotech presently has a consensus target price of $7.60, indicating a potential upside of 87.65%. Bicycle Therapeutics has a consensus target price of $13.86, indicating a potential upside of 255.31%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Summary

Alvotech and Bicycle Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Replimune Group presently has a consensus price target of $11.86, suggesting a potential downside of 20.79%. Bicycle Therapeutics has a consensus price target of $13.86, suggesting a potential upside of 255.31%. Given Bicycle Therapeutics' higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.60
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Replimune Group has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -128.57% -82.35%
Bicycle Therapeutics -311.11%-33.22%-27.79%

Replimune Group has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bicycle Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$313.94M-$3.38N/A
Bicycle Therapeutics$72.86M3.75-$218.96M-$2.73N/A

In the previous week, Replimune Group had 37 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 40 mentions for Replimune Group and 3 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.86 beat Replimune Group's score of 0.32 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
10 Very Positive mention(s)
3 Positive mention(s)
20 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Bicycle Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bicycle Therapeutics beats Replimune Group on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Jade Biosciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -49.11% -45.62%
Bicycle Therapeutics -311.11%-33.22%-27.79%

In the previous week, Jade Biosciences had 16 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 19 mentions for Jade Biosciences and 3 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.86 beat Jade Biosciences' score of 0.79 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicycle Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Jade Biosciences currently has a consensus target price of $51.75, suggesting a potential upside of 109.43%. Bicycle Therapeutics has a consensus target price of $13.86, suggesting a potential upside of 255.31%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Jade Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Jade Biosciences has higher earnings, but lower revenue than Bicycle Therapeutics. Jade Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$1.92N/A
Bicycle Therapeutics$72.86M3.75-$218.96M-$2.73N/A

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Jade Biosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Summary

Jade Biosciences and Bicycle Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Forte Biosciences?

Bicycle Therapeutics (NASDAQ:BCYC) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Forte Biosciences has lower revenue, but higher earnings than Bicycle Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$72.86M3.75-$218.96M-$2.73N/A
Forte BiosciencesN/AN/A-$69.38M-$4.64N/A

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Forte Biosciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics-311.11% -33.22% -27.79%
Forte Biosciences N/A -94.82%-77.68%

Bicycle Therapeutics presently has a consensus target price of $13.86, suggesting a potential upside of 255.31%. Forte Biosciences has a consensus target price of $72.50, suggesting a potential downside of 5.64%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Forte Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Forte Biosciences
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, Forte Biosciences had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for Forte Biosciences and 3 mentions for Bicycle Therapeutics. Forte Biosciences' average media sentiment score of 1.11 beat Bicycle Therapeutics' score of 0.86 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Forte Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bicycle Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market.

Summary

Bicycle Therapeutics beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

86.2% of Bicycle Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Odyssey Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Odyssey TherapeuticsN/AN/AN/A-$6.77N/A
Bicycle Therapeutics$72.86M3.75-$218.96M-$2.73N/A

Odyssey Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 59.19%. Bicycle Therapeutics has a consensus target price of $13.86, suggesting a potential upside of 255.31%. Given Bicycle Therapeutics' higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Odyssey Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44

Odyssey Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Odyssey Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Odyssey TherapeuticsN/A N/A N/A
Bicycle Therapeutics -311.11%-33.22%-27.79%

In the previous week, Bicycle Therapeutics had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 2 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.87 beat Bicycle Therapeutics' score of 0.86 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Odyssey Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicycle Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bicycle Therapeutics beats Odyssey Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCYC vs. The Competition

Export
MetricBicycle TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$278.57M$3.74B$7.06B$13.10B
Dividend YieldN/A3.69%2.57%10.45%
P/E Ratio-1.4310.67269.0625.28
Price / Sales3.751,294.08602.4391.76
Price / CashN/A102.8870.4850.90
Price / Book0.5316.7812.916.24
Net Income-$218.96M-$13.32M$3.45B$347.60M
7 Day Performance-6.47%1.74%1.12%1.07%
1 Month Performance-7.36%1.60%1.79%1.03%
1 Year Performance-47.15%56.43%67.69%20.77%

Bicycle Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCYC
Bicycle Therapeutics
3.4163 of 5 stars		$3.90
-2.0%		$13.86
+255.3%		-45.9%$278.57M$72.86MN/A240
ALVO
Alvotech
3.1578 of 5 stars		$3.79
+0.4%		$7.60
+100.8%		-54.4%$1.14B$588.90MN/A1,460
REPL
Replimune Group
1.7712 of 5 stars		$13.49
-1.3%		$11.86
-12.1%		+198.1%$1.13BN/AN/A210
JBIO
Jade Biosciences
2.4592 of 5 stars		$21.70
-0.2%		$52.29
+141.0%		+224.8%$1.07BN/AN/A20
FBRX
Forte Biosciences
1.8577 of 5 stars		$76.84
+0.0%		$72.50
-5.6%		+627.2%$1.07BN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The Shocking Discovery Investigators Found Hidden Inside America's Port Cranes
U.S. investigators found unexplained cellular modems inside cranes made by a Chinese state-owned company that ...
Altimetry | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel